Financial Performance - The company achieved operating revenue of CNY 709,207,754.74, representing a year-on-year increase of 11.68%[3] - Net profit attributable to shareholders reached CNY 137,695,535.22, up 14.18% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 125,121,243.57, reflecting a growth of 20.71%[3] - Basic earnings per share decreased by 6.28% to CNY 1.79[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1,154,207,194.69, an increase of 15.56% from the beginning of the period[3] - Shareholders' equity attributable to the company was CNY 948,062,246.15, up 15.93% from the beginning of the period[3] Research and Development - The company invested CNY 10,956,670 in R&D, a 69.35% increase year-on-year, with CNY 3,840,840 allocated to innovative drug development[6][7] Product Sales - The company reported stable growth in sales of key products, including rapid sales growth of Ipatasertib and Acarbose tablets[6] Capital Management - The company implemented a capital increase of 20% for every 10 shares held, affecting the net asset value per share, which decreased by 3.35% to CNY 12.12[7] Cost Control - The company emphasized cost control and efficiency improvements, contributing to enhanced profitability[6]
德源药业(832735) - 2023 Q4 - 年度业绩